Spero Therapeutics (SPRO) Competitors $2.15 +0.01 (+0.47%) Closing price 04:00 PM EasternExtended Trading$2.15 +0.00 (+0.05%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. ETON, ARCT, RGNX, ITOS, ESPR, CGEM, ERAS, CYRX, ZYBT, and PRTAShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Eton Pharmaceuticals (ETON), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), iTeos Therapeutics (ITOS), Esperion Therapeutics (ESPR), Cullinan Therapeutics (CGEM), Erasca (ERAS), CryoPort (CYRX), Zhengye Biotechnology (ZYBT), and Prothena (PRTA). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Eton Pharmaceuticals Arcturus Therapeutics REGENXBIO iTeos Therapeutics Esperion Therapeutics Cullinan Therapeutics Erasca CryoPort Zhengye Biotechnology Prothena Eton Pharmaceuticals (NASDAQ:ETON) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Do institutionals & insiders believe in ETON or SPRO? 27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 16.0% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ETON or SPRO more profitable? Eton Pharmaceuticals has a net margin of -7.10% compared to Spero Therapeutics' net margin of -110.35%. Eton Pharmaceuticals' return on equity of -0.73% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-7.10% -0.73% -0.22% Spero Therapeutics -110.35%-120.27%-55.61% Which has more volatility and risk, ETON or SPRO? Eton Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Does the media favor ETON or SPRO? In the previous week, Spero Therapeutics had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 4 mentions for Spero Therapeutics and 3 mentions for Eton Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 1.47 beat Spero Therapeutics' score of 0.91 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ETON or SPRO? Eton Pharmaceuticals presently has a consensus target price of $29.67, indicating a potential upside of 67.89%. Spero Therapeutics has a consensus target price of $5.00, indicating a potential upside of 132.56%. Given Spero Therapeutics' higher possible upside, analysts clearly believe Spero Therapeutics is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation & earnings, ETON or SPRO? Eton Pharmaceuticals has higher earnings, but lower revenue than Spero Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M12.15-$3.82M-$0.16-110.44Spero Therapeutics$47.98M2.52-$68.57M-$0.98-2.19 SummaryEton Pharmaceuticals beats Spero Therapeutics on 11 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$120.43M$3.15B$5.76B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-2.1921.1075.6026.68Price / Sales2.52431.08538.82209.12Price / CashN/A45.1137.1158.92Price / Book2.539.8611.446.09Net Income-$68.57M-$53.47M$3.28B$266.14M7 Day Performance3.86%2.89%0.84%0.28%1 Month Performance1.42%8.62%7.15%4.14%1 Year Performance61.65%13.69%59.66%23.93% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.4196 of 5 stars$2.15+0.5%$5.00+132.6%+63.4%$120.43M$47.98M-2.19150News CoverageShort Interest ↓ETONEton Pharmaceuticals2.3542 of 5 stars$17.31+0.2%$29.67+71.4%+287.6%$464.21M$39.01M-108.1920Positive NewsARCTArcturus Therapeutics3.5767 of 5 stars$17.01-1.7%$50.57+197.3%-12.1%$461.90M$152.31M-7.63180News CoveragePositive NewsAnalyst ForecastRGNXREGENXBIO4.6195 of 5 stars$8.93-0.9%$28.38+217.7%-16.5%$451.09M$83.33M-2.60370News CoveragePositive NewsGap UpITOSiTeos Therapeutics3.8442 of 5 stars$10.15flat$15.50+52.7%N/A$448.68M$35M-2.1790News CoverageShort Interest ↓ESPREsperion Therapeutics3.8339 of 5 stars$2.22+0.5%$7.00+215.3%+39.0%$447.60M$332.31M-4.53200Options VolumeCGEMCullinan Therapeutics3.0355 of 5 stars$7.54-0.9%$26.80+255.4%-63.0%$445.42MN/A-2.3330Positive NewsERASErasca2.8575 of 5 stars$1.57flat$4.29+173.0%-47.0%$445.36MN/A-3.49120Positive NewsAnalyst ForecastCYRXCryoPort3.5408 of 5 stars$8.86+2.0%$12.00+35.4%+3.4%$443.59M$228.38M6.661,186News CoveragePositive NewsZYBTZhengye BiotechnologyN/A$9.36+5.5%N/AN/A$441.48M$25.53M0.00278News CoverageGap UpPRTAProthena3.6063 of 5 stars$8.20-0.5%$22.00+168.3%-60.7%$441.41M$135.16M-1.45130News CoverageAnalyst Forecast Related Companies and Tools Related Companies Eton Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives REGENXBIO Alternatives iTeos Therapeutics Alternatives Esperion Therapeutics Alternatives Cullinan Therapeutics Alternatives Erasca Alternatives CryoPort Alternatives Zhengye Biotechnology Alternatives Prothena Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRO Stock Alerts